View More
Slides from Arjun Balar, MD on optimal selection of first-line treatment for patients with advanced urothelial cancer, from Clinical Care Options (CCO)
Arjun Balar, MD
Released: May 6, 2021
Expert insight from Arjun Balar, MD, on choosing optimal first-line therapy for patients with advanced urothelial or bladder cancer, from Clinical Care Options (CCO)
Arjun Balar, MD
Kaitlynn Francese, MSN, RN, OCN
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Pharmacists:
0.25 contact hours (0.025 CEUs)
Released: May 6, 2021
Expired:
May 5, 2022
Expert insight from Arjun Balar, MD, on choosing optimal therapy for patients with advanced urothelial cancer after chemo and IO, from Clinical Care Options (CCO)
Arjun Balar, MD
Kaitlynn Francese, MSN, RN, OCN
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Pharmacists:
0.25 contact hours (0.025 CEUs)
Released: May 4, 2021
Expired:
May 3, 2022
Slides from Arjun Balar, MD on the role of antibody-drug conjugates in early stage urothelial cancer, from Clinical Care Options (CCO)
Arjun Balar, MD
Released: May 4, 2021
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.